Modulation of CD6 function through interaction with Galectin-1 and -3  by Escoda-Ferran, Cristina et al.
FEBS Letters 588 (2014) 2805–2813journal homepage: www.FEBSLetters .orgModulation of CD6 function through interaction with Galectin-1 and -3qhttp://dx.doi.org/10.1016/j.febslet.2014.05.064
0014-5793/ 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Abbreviations: ALCAM, Activated Leukocyte Cell Adhesion Molecule; Gal-1/-3,
Galectin-1/-3; PRRs, pattern-recognition receptor; CRD, carbohydrate-recognition
domains; DC, dendritic cell; TEC, thymic epithelial cells; SRCR-SF, scavenger
receptor cysteine-rich superfamily; rshCD5/6, recombinant soluble human CD5/6;
o/n, overnight; TMB, 3,30 ,5,50-tetramethylbenzidine; RT, room temperature; LTA,
lipoteichoic acid; PGN, peptidoglycan; PFA, paraformaldehyde; PE, phycoerithrin;
SEB, staphylococcal enterotoxin B; Kd, dissociation constant
q This study was supported by grants from the Spanish Ministerio de Economía y
Competitividad (SAF2010-19717), Generalitat de Catalunya (2009SGR1101), and
Instituto de Salud Carlos III (Spanish Network for Research in Infectious Diseases,
REIPI, RD12/0015/0018). C.E.-F., E.C., C.M.-J., and V.G.M. are recipients of fellowships
from Spanish Ministerio de Economía y Competitividad (FPI BES2008-005544, FPU
AP2007-02223, JCI-2008-3294, and BES-2008-005544, respectively). M.M.-F. is
recipient of a fellowship from Agència de Gestió d’Ajuts Universitaris i de Recerca
(AGAUR) of the Generalitat de Catalunya (2010TEM37).
⇑ Corresponding author at: Centre Esther Koplowitz, Rosselló 149-153, 08036
Barcelona, Spain. Fax: +34 934518038.
E-mail address: ﬂozano@clinic.ub.es (F. Lozano).Cristina Escoda-Ferran a, Esther Carrasco a, Miguel Caballero-Baños b, Cristina Miró-Julià a,
Mario Martínez-Florensa a, Marta Consuegra-Fernández a, Vanesa G. Martínez a, Fu-Tong Liu c,
Francisco Lozano a,b,d,⇑
a From Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centre Esther Koplowitz, 08036 Barcelona, Spain
b Servei d’Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, 08036 Barcelona, Spain
cDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA 95816, United States
dDepartament de Biologia Cel lular, Immunologia i Neurociències, Facultat de Medicina Universitat de Barcelona, 08036 Barcelona, Spaina r t i c l e i n f o
Article history:
Received 15 May 2014
Accepted 20 May 2014
Available online 16 June 2014
Edited by Beat Imhof
Keywords:
CD6
ALCAM/CD166
Galectin
T-cell activation
Cell adhesion
Apoptosisa b s t r a c t
CD6 is a lymphocyte glycoprotein receptor that physically associates with the antigen-speciﬁc recep-
tor complex at the center of the immunological synapse, where it interacts with its ligand CD166/
ALCAM. The present work reports the carbohydrate-dependent interaction of CD6 and CD166/ALCAM
with Galectin-1 and -3, two well-known soluble mammalian lectins. Both galectins interfered with
superantigen-induced T cell proliferation and cell adhesion phenomena mediated by the CD6-
CD166/ALCAM pair, while CD6 expression protected cells from galectin-induced apoptosis. The
results suggest that interaction of Galectin-1 and -3 with CD6 and CD166/ALCAM might modulate
some relevant aspects of T cell physiology.
Structured summary of protein interactions:
Gal-3 binds to CD6 by pull down (View interaction)
Gal-1 binds to CD6 by pull down (View interaction)
Gal3 binds to ALCAM by pull down (View interaction)
Gal1 binds to ALCAM by pull down (View interaction)
Gal-3 binds to CD6 by enzyme linked immunosorbent assay (View interaction)
Gal-1 binds to CD6 by enzyme linked immunosorbent assay (View interaction)
ALCAM binds to Gal3 by enzyme linked immunosorbent assay (1, 2)
ALCAM binds to Gal1 by enzyme linked immunosorbent assay (View interaction)
ALCAM physically interacts with Gal1 and CD6 by competition binding (View interaction)
CD6 binds to ALCAM by enzyme linked immunosorbent assay (View interaction)
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Galectins are a family of evolutionarily conserved animal lectins
serving as pattern-recognition receptors (PRRs) [41], which have
attracted recent interest as regulators of immune responses
[19,30]. The carbohydrate-recognition domains (CRDs) of galectins
speciﬁcally bind to b-galactoside-containing cell surface receptors
and subsequently trigger signaling events, modulating cellular pro-
cesses such as cell growth, survival, adhesion, cytokine secretion or
migration [19].
Galectin (Gal)-1 and -3 are the most ubiquitously expressed and
most widely studied members of the galectin family. Within the
immune system, they are co-expressed in many cells from primary
and secondary lymphoid organs, with their expression levels
depending on the cell activation and differentiation status [36].
These include thymic epithelial cells (TEC) [45,4], activated T cells
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[40,29,36], dendritic cells (DCs), endothelial cells and ﬁbroblasts
[32]. Both Gal-1 and -3 bind to T cells through recognition of still
not fully characterized and not fully overlapping surface glycopro-
teins, including CD29, CD43 and CD45 [44], among others. Through
these interactions, Gal-1 and -3 have been shown to modulate
multiple T cell functions, both in vitro and in vivo [30,20].
CD6 is a surface receptor belonging to the scavenger receptor
cysteine-rich superfamily (SRCR-SF), another ancient and highly
conserved group of innate-like receptors, characterized by the
presence of one or several repeats of a cysteine-rich extracellular
domain named SRCR [21,33]. CD6 is mainly expressed on lympho-
cytes (thymocytes, mature T cells, NK cells and B1a cells) [3,16,9],
but also on hematopoietic cell precursors [10] and certain brain
regions [17]. There it plays a double role as a PRR and also as an
accessory molecule involved in cell signaling and cell–cell adhe-
sion contacts taking place during lymphocyte activation and differ-
entiation [21,8,28]. The latter is essentially achieved through its
physical association to the TCR/CD3 complex [11], as well as its
interaction with CD166/ALCAM (Activated Leukocyte Cell Adhe-
sion Molecule), an adhesion molecule of the Ig superfamily [27].
Moreover, CD6 co-localizes with the TCR/CD3 complex at the cen-
tre of the immunological synapse [11], where its interaction with
CD166/ALCAM results critical for maturation and stabilization of
this signaling structure as well as for subsequent T cell prolifera-
tive responses [11,13,47]. This, together with multiple functional
studies with anti-CD6 mAbs, has resulted in CD6 being considered
as an important T cell co-stimulatory molecule [34]. However, this
view was recently challenged by data suggesting that CD6 could
also act as a negative regulator of T cell activation [25].
Given that CD6 is a glycoprotein, and that some members of the
SRCR-SF interact with galectins [14,23,39], potential interactions
between CD6 and Gal-1 and -3 and their consequences have been
explored. The results indicate that both galectins interact not only
with CD6 but also with its ligand CD166/ALCAM in a carbohydrate-
dependent manner. In this way, Gal-1 and -3 are shown to modu-
late several lymphocyte functions dependent on CD6- and CD166/
ALCAM-mediated interactions.
2. Experimental procedures
2.1. Production and puriﬁcation of chimerical recombinant proteins
Recombinant soluble human CD5 (rshCD5), CD6 (rshCD6), and
ALCAM-Fc proteins were produced and puriﬁed as described
[11,24,38].
pGex constructs coding for WT (rhGal3) and mutant (R186S)
human Gal-3, and for Glutathione S-transferase (GST) fusion pro-
teins (GST-Gal1, GST-Gal3) were kindly provided by Fu-Tong Liu,
and H. Lefﬂer (Lund University, Sweden) and expressed in Esche-
richia coli BL21 strain. For protein production, bacteria were grown
at 37 C in 2YT broth supplemented with 0.1 mg/ml of ampicillin
until absorbance at 600 nm reached 0.5–0.8. Then 0.2 mM Isopropyl
b-D-1-thiogalactopyranoside was added and bacteria cultured at
25 C overnight (o/n). Bacterial pellets were resuspended in 60 ml
of lysis buffer (20 mM Tris–HCl pH 7.5, plus 5 mM EDTA, 20 mM
b-mercaptoethanol (ME), 10 mM sucrose, and 2.5 ml Complete pro-
tease inhibitor (Roche), and sonicated three times. The supernatant
was clariﬁed by centrifugation and then incubated at 4 C for 2 h
with 1.5 ml of Glutathione Sepharose 4B (GE Healthcare) beads
(50%, v/v). After extensive washings with lysis buffer (omitting
EDTA) and 20 mM Tris–HCl, pH 7.5, GST proteins were eluted by
addition of 50 mM Tris–HCl pH 8.0 plus 10 mM glutathione for
10 min at room temperature (RT). The sameprocedurewas followed
for production of WT and R186S rhGal3, except that bacterialsolubilisates were loaded onto a Lactosyl-Sepharose column
(Sigma–Aldrich) and protein eluted by addition of PBS plus 25 mM
lactose and 10 mM b-ME.
Endo Trap red columns (Hyglos GmbH) were used to remove
endotoxin from all the recombinant and chimerical protein prepa-
rations used in this study, following manufacturer’s instructions.
Chimerical or recombinant proteins were biotin-labeled using
EZ-Link Sulfo-NHS-LC-LC-Biotin (Thermo Scientiﬁc), following
manufacturer’s instructions.
2.2. Pull-down assays
GST-Gal proteins adsorbed onto Glutathione Sepharose beads
were blocked in TBS plus 5% BSA, and then incubated o/n at 4 C
with 0.1 lg biotin-labeled proteins (rshCD6, rshCD5) or ALCAM-
Fc, in the presence or absence of increasing concentrations of lac-
tose or sucrose. Beads were then washed three times with TBS
and bound proteins were eluted with Laemmli’s sample buffer
and separated by 8% SDS–PAGE for further Western blot analysis
with HRP-labeled streptavidin (Roche) or HRP-labeled F(ab0)2
anti-human Ig Fc antiserum (Jackson Immunoresearch), and devel-
opment by chemiluminescence (Supersignal West Dura Extended
Duration Solution, Pierce).
2.3. ELISA assays
96-well plates (Nunc, Roskilde, Denmark) coated o/n at 4 C
with puriﬁed GST-Gal1, GST-Gal3 or GST (1 lg/well) were blocked
with PBS plus 3% BSA. Plates were then incubated with biotinylated
rshCD5 or rshCD6 and bound protein was detected with
HRP-labeled streptavidin (Roche). Color was developed by adding
3,30,5,50-tetramethylbenzidine (TMB) liquid substrate (Sigma) and
absorbance measured at 450 nm.
Interaction of galectins with ALCAM-Fc was analyzed as above,
except that plates were coated with ALCAM-Fc (1 lg/well) and
then assayed for binding to biotinylated GST-Gal1, GST-Gal3 or
GST proteins.
Similarly, interaction of WT or mutant rhGal3 with CD6 or
ALCAM-Fc was performed by coating plates with rhGal3 or
R186S (1 lg/well) and incubating them with either biotin-labeled
rshCD6 or unlabeled ALCAM-Fc. Bound proteins were detected
with HRP-streptavidin or HRP-labeled F(ab0)2 anti-human Ig Fc
antiserum (Jackson Immunoresearch), respectively.
Competition assays were performed by coating plates with lipo-
polysaccharide (LPS) from E. coli K12 O111:B4, lipotheichoic acid
(LTA) or peptidoglycan (PGN) from Staphylococcus aureus (Sigma)
or ALCAM-Fc (all at 1 lg/well). Then, a ﬁxed amount (500 ng) of
biotin-labeled rshCD6 was pre-incubated with increasing concen-
trations of unlabeled puriﬁed GST-Gal1, GST-Gal3 or GST proteins
and added to the wells for further detection with HRP-streptavidin
and TMB as above.
2.4. Cell adhesion assays
96-well plates coated o/n at 4 C with puriﬁed rshCD6 or
ALCAM-Fc (1 lg/well) were blocked with RPMI 1640 plus 0.5%
BSA. Then, 105 RAJI B-cells (ALCAM+) or Jurkat T-cells (CD6+)
(American Tissue Culture Collection) were added to wells, respec-
tively, and left to adhere for 30 min at 37 C in the presence or
absence of different amounts of puriﬁed GST, GST-Gal1,
GST-Gal3, rshCD6 or ALCAM-Fc proteins. After washing, adhered
cells were ﬁxed with 4% paraformaldehyde (PFA) for 15 min and
washed before adding crystal violet diluted in 2% ethanol. The plate
was then extensively washed with water and cell adhesion was
analyzed by adding 2% SDS and measuring absorbance at 620 nm.
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Analysis of CD6 surface expression in 2G5 cells, a CD5- and CD6-
deﬁcient Jurkat cell line derivative [42], either untransfected (2G5)
or transfectedwithWT (2G5-CD6.WT)or cytoplasmic-tail truncated
(2G5-CD6.V463stop) CD6 forms [12] was performed by stainingwith
FITC-labeledmouseanti-humanCD6mAb (M-T605;BDPharmigen).
FITC-labeled IgG1 mouse isotype control (MG101; Life Technolo-
gies) was used as negative control. Cell ﬂuorescence was assessed
with a FACSCanto II ﬂow cytometer and analyzed by FlowJo
software.
Cell-binding properties of galectins were assessed on parental
and CD6-transfected 2G5 cells. Brieﬂy, 105 cells were incubated
for 1 h at 4 C with 5 lg/ml of biotin-labeled GST, GST-Gal1 or
GST-Gal3 proteins. After extensive washing, cells were then
incubated for with phycoerythrin (PE)-labeled streptavidin (Caltag
Laboratories), and ﬂuorescence assessed by FACS as above.
2.6. Apoptosis assay
2G5 cells (2  105), either untransfected or stably expressing
WT (2G5-CD6.WT) or cytoplasmic tail-truncated (2G5-CD6.V463stop)
CD6 forms, were suspended in FCS-free RPMI 1640 medium
(Lonza) and incubated for 30 min at 37 C in the presence of
100 lg/ml of GST, GST-Gal1 or GST-Gal3. Apoptotic cells were then
detected using the Annexin V-FITC Apoptosis Detection kit follow-
ing manufacturer’s instructions (Immunostep). Cell ﬂuorescence
was assessed as above and expressed as percent of Annexin V- FITC
positive cells.
2.7. T-cell proliferation assays
Peripheral blood lymphocytes (PBLs) were labeled with car-
boxyﬂuorescein succinimidyl ester (CFSE; Invitrogen) following
manufacturer’s instructions. Mature DCs were obtained by cultur-
ing plastic-adherent monocytes for 7 days in X-VIVO 15 (Lonza)
supplemented with 2% autologous serum, 1000 U/ml GM-CSF
(Miltenyi Biotech) and 1000 U/ml IL-4 (Miltenyi Biotec), and then
for an additional 24 h in the presence of 20 ng/ml TNF-a (Miltenyi
Biotech), 10 ng/ml IL1-b (Miltenyi Biotech), 20 ng/ml IL-6 (Miltenyi
Biotech), 1 lg/ml prostaglandin E2 (PGE2; Dinoprostona, Pﬁzer),
and 20 mg/ml poly(I:C) (Hiltonol; Oncovir). Proliferation assays
were conducted by pre-incubating mature DCs (2  103) with
1 lg/ml staphylococcal enterotoxin B (SEB; Sigma) for 30 min
and then co-culturing for 5 days at 37 C with CFSE-labeled PBLs
(105) from an unrelated donor. Where indicated, rshCD6, GST,
GST-Gal1, and GST-Gal3 (0.5, 5 and 50 lg/ml) were added at the
co-culture onset. Proliferation was assessed by ﬂow cytometry by
loss of CFSE dye in viable lymphocytes gated by forward and side
scatter criteria. Cell viability was assessed for each experimental
condition by trypan blue dye exclusion.
3. Results
3.1. Gal-1 and -3 interact with CD6 in a dose- and carbohydrate-
dependent manner
The putative interaction of CD6 with Gal-1 and -3 was ﬁrst
explored by ELISA assays using afﬁnity-puriﬁed GST-Gal1/3 fusion
proteins (Fig. 1A) and biotin-labeled recombinant soluble human
CD5/6 (rshCD5/6) proteins. rshCD6 interacted with both
GST-Gal1 and GST-Gal3 in a dose-dependent manner (Fig. 1B–D),
which was speciﬁc since no binding of rshCD6 to GST alone was
observed, and the highly homologous rshCD5 protein did not show
any signiﬁcant interaction with either GST-Gal1 or GST-Gal3.Further demonstration of the interaction of Gal-1 and -3 with
CD6 was obtained from pull-down assays using GST-Gal1/3
adsorbed onto Glutathione Sepharose beads and biotin-labeled
rshCD6, in the presence or absence of increasing concentrations
(1.5–15 mM) of competing sugars. As shown by Fig. 1E and F,
rshCD6 interacted with both GST-Gal1 and GST-Gal3. Intriguingly,
two bands were consistently observed in the gels, thus indicating
that not all rshCD6 forms but only those with higher and lower
molecular weight (m.w.) interacted with GST-Gal1 and –Gal3
Sepharose beads. This interaction was competed in a dose-depen-
dent manner by speciﬁc (lactose) but not irrelevant (sucrose) sug-
ars. Taken together, results suggest that the CRDs of Gal-1 and -3
are involved in binding to some but not all isoforms of CD6. CRD
involvement was further supported by ELISA assays (Fig. 1G)
demonstrating that biotin-labeled rshCD6 bound to WT Gal-3
(rhGal3) but not to a mutated form (R186S) that lacks afﬁnity for
N-acetyllactosamine [37].
3.2. Gal-1 and -3 interfere with recognition of endogenous
and exogenous ligands by CD6
To shed light on the biological consequences resulting from
Galectin-1/-3 (Gal-1/-3) interaction with CD6, a series of competi-
tion ELISA assays were performed using biotin-labeled rshCD6 and
well-known endogenous (CD166/ALCAM) [8] or exogenous (bacte-
rial PAMPs) [38,22] ligands in the presence of increasing concen-
trations of unlabeled puriﬁed GST-Gal-1/3. Both GST-Gal1 and
GST-Gal3 competed the binding of rshCD6 to PAMPs of both
Gram-negative (LPS) and Gram-positive (LTA, PGN) origin in a
dose-dependent manner (Fig. 2A–C). Similarly, GST-Gal1/3 also
competed the binding of rshCD6 to ALCAM-Fc (Fig. 2D). No com-
petitive effects were observed for GST alone in any of the assays.
Although steric hindrance phenomena in solution cannot be ruled
out, these results suggest that Gal-1 and -3 could speciﬁcally
interfere with CD6-ligand interactions.
3.3. Gal-1 and -3 interact with CD166/ALCAM
in a dose- and carbohydrate-dependent manner
Since CD166/ALCAM is heavily glycosylated, potential direct
binding of Gal-1 or -3 to CD166/ALCAM was further investigated.
ELISA assays showed a dose-dependent interaction of biotin-
labeled GST-Gal1 and GST-Gal3 proteins – but not GST alone – to
plate-bound ALCAM-Fc (Fig. 3A). Pull-down assays also showed
that ALCAM-Fc bound to GST-Gal1 (Fig. 3B) or GST-Gal3 (Fig. 3C)
beads, and that such an interaction was competed by speciﬁc (lac-
tose) but not irrelevant (sucrose) sugars in a dose-dependent man-
ner. Taken together, these results indicate that Gal-1 and -3
recognize speciﬁc carbohydrate structures present not only on
CD6 but also on its ligand CD166/ALCAM. Further evidence of the
CRD involvement in this interaction was obtained from ELISA
assays demonstrating binding of ALCAM-Fc to plate-bound WT
Gal-3 (rhGal3) but not to the mutant rhGal3 R186S protein
(Fig. 3D).
3.4. Gal-1 and -3 modulate cell adhesion mediated
by CD6 -CD166/ALCAM interaction
The functional relevance of Gal-1/-3 interaction with CD6 and
CD166/ALCAM was ﬁrst explored by investigating the adhesion of
RAJI B cells (CD166/ALCAM+) to plate-bound rshCD6 in the presence
of increasing concentrations of GST-Gal proteins. As shown by
Fig. 4A, bothGST-Gal1 andGST-Gal3 – but notGST alone – competed
the adhesion of RAJI cells to CD6-coated plates in a dose-dependent
manner.
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Fig. 1. Gal-1 and -3 interact with the extracellular domain of human CD6 in a dose- and carbohydrate-dependent manner. (A) SDS–PAGE analysis of afﬁnity-puriﬁed
recombinant proteins used in this study: GST (Lane 1), GST-Gal1 (Lane 2), GST-Gal3 (Lane 3), rhGal3 (Lane 4), mutant rhGal3 (R186S) (Lane 5), rshCD5 (Lane 6), rshCD6 (Lane
7), and ALCAM-Fc (Lane 8). Protein samples (2 lg) were separated on 8% SDS–PAGE under reducing conditions and then stained with Coomassie blue. (B–D) ELISA assays
showing speciﬁc and dose-dependent interaction of GST-Gal1 and -Gal3 with rshCD6. ELISA plates coated with GST-Gal1 (B), GST-Gal3 (C) or GST (D) were incubated with
increasing amounts of biotin-labeled rshCD6 or rshCD5 and then developed with HRP-streptavidin and TMB substrate solution. Absorbance at 450 nm of triplicates from
three independent experiments is represented. (E–F) Pull-down assays showing carbohydrate-dependent interaction of GST-Gal1 and -Gal3 with rshCD6. GST-Gal1 (E) or
GST-Gal3 (F) beads were incubated with biotin-labeled rshCD6 (0.1 lg) in the presence or absence of increasing concentrations (1.5, 3, and 15 mM; +, ++, and +++,
respectively) of lactose or sucrose. Bound proteins were analyzed by Western blotted and developed with HRP-streptavidin and chemiluminescence. (G) N-
acetyllactosamine-binding deﬁcient Gal-3 mutant does not bind to rshCD6. ELISA plates coated with increasing amounts of WT (rhGal3) or mutant (R186S) Gal-3 were
incubated with a ﬁxed amount of biotin-labeled rshCD6 (1.25 lg/ml) and then developed with HRP-streptavidin and TMB. Absorbance at 450 nm of triplicates from three
independent experiments is represented.
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assays, CD6- or ALCAM-Fc-coated plates were pre-incubated with
excess amounts of GST-Gal1 or -Gal3 before addition of RAJI
(CD166/ALCAM+) or Jurkat (CD6+) cells, respectively. Under these
conditions, GST-Gal1 or GST-Gal3 - but not GST alone – signiﬁcantly
reduced cell adhesion of RAJI (Fig. 4B) but not Jurkat cells (Fig. 4C).
In all these experiments, pre-incubation with ALCAM-Fc or rshCD6
and GST alone were used as positive and negative controls, respec-
tively, which behaved as expected. These results indicate that the
modulatory effects of both Gal-1 and -3 on cell adhesion mediatedby CD6-CD166/ALCAM interaction might be attributable to their
binding to CD6 but not to CD166/ALCAM.
3.5. Membrane-bound CD6 binds to Gal-1 and -3 and modulates
galectin-induced apoptosis
To conﬁrm that Gal-1 and -3 were also able to interact with
membrane-bound CD6, biotin-labeled soluble GST-Gal proteins
were incubated with parental and CD6-transfected 2G5 cells, a
CD6-negative Jurkat cell line derivative (Fig. 5A), and analyzed by
A C
B D
(μg/mL)
(μg/mL)
(μg/mL)
(μg/mL)
Fig. 2. Gal-1 and -3 interfere with the ligand-binding properties of CD6. (A–C) Binding of CD6 to bacterial PAMPs is competed by Gal-1 and Gal-3 in a dose-dependent
manner. ELISA plates coated with 1 lg/well of LPS (A), LTA (B) or PGN (C) were incubated with a ﬁxed amount of biotin-labeled rshCD6 (500 ng) in the presence or absence of
increasing concentrations of GST-Gal1 (open circles), GST-Gal3 (open squares) or GST (open triangles). Bound biotinylated protein was detected by using HRP-streptavidin
and TMB. Absorbance at 450 nm of triplicates from three independent experiments is represented. (D) Binding of CD6 to CD166/ALCAM is competed by GST-Gal1 and -Gal3 in
a dose-dependent manner. The same ELISA assays as in A–C were performed except that plates were coated with ALCAM-Fc (0.5 lg/well).
A B
DC
(μg/mL)
(μg/mL)
Fig. 3. Gal-1 and -3 interact with CD166/ALCAM in a dose- and carbohydrate-dependent manner. (A) ELISA assays showing dose-dependent interaction of Gal-1 and -3 with
CD166/ALCAM. ALCAM-Fc-coated plates (0.5 lg/well) were incubated with increasing amounts of biotin-labeled GST-Gal1, GST-Gal3 or GST. Bound protein was detected
with HRP-streptavidin and TMB. Absorbance at 450 nm of triplicates from three independent experiments is represented. (B and C) Pull-down assays showing carbohydrate-
dependent interaction of Gal-1 and -3 with CD166/ALCAM. GST-Gal1 or GST-Gal3 beads were incubated with ALCAM-Fc (0.1 lg) in the presence or absence of increasing
concentrations (1.5, 3, and 15 mM; +, ++, and +++, respectively) of lactose or sucrose. Bound proteins were analyzed by Western blotted and developed with HRP-labeled
F(ab0)2 anti-human Ig Fc and chemiluminescence. (D) N-acetyllactosamine-binding deﬁcient Gal-3 mutant does not bind to CD166/ALCAM. ELISA plates coated with rshCD6,
rhGal3 or R186S (1 lg/well) were incubated with increasing amounts of ALCAM-Fc and then developed with HRP-labeled F(ab0)2 anti-human Ig Fc and TMB. Absorbance at
450 nm of triplicates from three independent experiments is represented.
C. Escoda-Ferran et al. / FEBS Letters 588 (2014) 2805–2813 2809ﬂow cytometry. A signiﬁcantly higher mean ﬂuorescence intensity
channel was observed following incubation of GST-Gal1/3 with
transfected (2G5-CD6) than with parental 2G5 cells (Fig. 5B andC). This was not due to differences in autoﬂuorescence between
parental and transfected 2G5 cells, since negative controls (bio-
tin-labeled GST followed by PE-streptavidin) for both cell types
AC
(μg/ml)
B
Fig. 4. Gal-1 and -3 compete cell adhesion mediated by CD6-CD166/ALCAM
interaction in a speciﬁc and dose-dependent manner. (A) Adhesion of RAJI cells
(ALCAM+) to plate-bound CD6 is competed by Gal-1 and -3. RAJI cells (105/well)
pre-incubated with increasing amounts of GST-Gal1, GST-Gal3 or GST (12.5, 25, and
50 lg/ml) were allowed to adhere to rshCD6-coated plates (1 lg/well). After
extensive washing, cells were ﬁxed and then stained with crystal violet. Cell
adhesion was quantiﬁed by adding 2% SDS solution and further reading of
absorbance at 620 nm. (B) Gal-1 and -3 interfere with RAJI cell adhesion to plate-
bound CD6. ELISA plates coated with rshCD6 (1 lg/well) were incubated with
ALCAM-Fc, GST-Gal1 or GST-Gal3 (10 lg/ml). Excess unbound proteins were
washed out, and then RAJI (105) cells were added and processed as in A. (C) Gal-1
and -3 do not interfere Jurkat cell adhesion to plate-bound ALCAM-Fc. ELISA plates
coated with ALCAM-Fc (1 lg/well) were incubated with rshCD6, GST-Gal1, GST-
Gal3 or GST (10 lg/ml each). Following protein excess removal, 105 Jurkat cells
were added and then processed as in B. In all cases, results are represented as
percent (%) of maximal cell adhesion of triplicates from three independent
experiments. Statistical analyses were performed comparing the different condi-
tions with the condition without competitor and using an unpaired t-test. ⁄p < 0.02;
⁄⁄p < 0.01; ⁄⁄⁄p < 0.0001.
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and Gal-3 binding to 2G5 cells, showing that these galectins are
able to interact with membrane-bound CD6 from lymphoid T cells.
The functional relevance of this interaction was further
explored by galectin-induced apoptosis assays. As illustrated by
Fig. 6, 2G5 transfectants expressing WT CD6 (CD6.WT) showed
decreased apoptosis levels induced by GST-Gal1 (Fig. 6A) or -
Gal3 (Fig. 6B) with regard to parental 2G5 cells. Interestingly,
transfectants expressing a cytoplasmic tail-truncated form of CD6
(CD6.V463stop) showed the opposite effect, increasing apoptosis
levels above those of parental 2G5 cells. As expected, no apoptosis
was induced by GST alone (Fig. 6C). These results indicate that Gal-
1/3-induced apoptosis can be modulated by CD6 surface expres-
sion, and that the net effect on the cell depends on the integrity
of its cytoplasmic tail.
3.6. Gal-1 and -3 negatively modulate T-cell proliferation induced by
superantigen-loaded mature DCs
Binding of CD6 to CD166/ALCAM has been shown to be critical
not only for stable DC-T cell conjugate formation but also forallogeneic T-cell proliferative responses in the presence of super-
antigen [11,13,47]. To further analyze whether Gal-1/3 could inter-
fere the latter, mature DCs pre-incubated with SEB superantigen
were co-cultured for 5 days with CFSE-labeled allogeneic PBLs in
the presence of increasing concentrations of GST-Gal1 or – Gal3.
Both proteins – but not GST alone – signiﬁcantly reduced T-cell
proliferation in a dose-dependent manner (Fig. 7). This inhibitory
effect was not attributable to direct toxic effects of Gal-1 or -3
since cell viability was similar in all co-cultures. Interestingly,
the magnitude of the inhibitory effects observed for rshCD6 – used
here as a positive control of speciﬁc interference of the
CD6-ALCAM interaction – was similar to that attained by
GST-Gal1 and -Gal3.
4. Discussion
The present study reports the identiﬁcation of Gal-1 and -3 as
two new ligands for CD6, as well as for its counter-receptor,
CD166/ALCAM, and opens the possibility that this could be exten-
sive to other members of the galectin family. Interaction of both
galectins with other members of the SRCR and the Ig superfamilies
have already been reported. In the case of the SRCR-SF, only Mac-2
Binding Protein [39], Hensin [14] and S5D-SRCRB [23] have been
reported to bind to galectins; this indicates that interaction with
galectins is not a general property of SRCR-containing proteins.
This is here well exempliﬁed here by the lack of interaction of
Gal-1/3 with CD5, a highly homologous receptor to CD6 [21]. A
similar situation would apply to Ig domain-containing proteins.
This is very likely due to the fact that, although protein–protein
interactions are feasible, most of the interactions reported for
galectins are carbohydrate-dependent. Again, this is here exempli-
ﬁed by Gal-1/3 interacting only with certain isoforms of CD6. Sialy-
lation as well as other modiﬁcations of N- and O-linked glycan
structures are known to negatively impact on galectin binding
[41]. Thus, CD6-galectin interactions might be dependent on
changes in the activity of certain glycosyltransferases taking place
during the activation and differentiation of lymphoid cells, as
reported for other lymphocyte surface receptors [2,30].
The evidence presented herein also indicates that the interac-
tion of Gal-1/3 with CD6 could be of functional relevance since it
interferes with the binding of CD6 to its previously reported
endogenous (CD166/ALCAM) and exogenous (bacterial PAMPs)
ligands. The ultimate consequences of the interaction of CD6 with
bacterial ligands (e.g., LPS) regarding lymphocyte activation and
differentiation remain to be deciphered [18]. It can be, however,
hypothesized that these interactions would be competed by galec-
tins in light of the present data. Indeed, expression of galectins is
increased in situations of bacterial aggression and they are also
known to bind to bacterial products such as LPS [19].
The interaction of CD6 with CD166/ALCAM has been exten-
sively mapped [8] and is known to occur through the interaction
of the most membrane-proximal domain (SRCR3) of CD6 with
the most N-terminal Ig domain (D1) of CD166/ALCAM. This inter-
action is critical in different physiological situations involving
cell-to-cell contact, such as developing thymocytes binding to
TEC [27,43], and APC-mediated T-cell proliferation [13,47]. These
processes should from now on be considered susceptible of regula-
tion by galectins via interaction with either CD6 or CD166/ALCAM.
This is in agreement with experimental data showing that both
Gal-1 and -3 are expressed by TEC and that Gal-3 accelerates the
de-adhesion of thymocytes from thymic nurse cells [4,45]. Inter-
estingly, control of these adhesion-dependent phenomena by
Gal-1 and -3 appears to be uni-directional, since it is only achieved
when galectins bind to CD6 but not to CD166/ALCAM. From this it
could also be inferred that interaction with Gal-1 and -3 involves at
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Fig. 6. Modulation of galectin-induced T cell apoptosis by CD6 isoform expression. (A) Differential modulation of Gal1-induced apoptosis by CD6 isoforms. Parental and CD6-
transfected 2G5 cells (2  105) expressing WT (2G5-CD6.WT) or cytoplasmic tail-truncated (2G5-CD6.V463stop) isoforms were exposed to GST-Gal1 (100 lg/ml, each) for
30 min at 37 C and then analyzed by FACS for quantiﬁcation of cell apoptosis by Annexin V-FITC staining. A representative experiment is shown on the left panel. The percent
(%) of apoptotic cells averaged from two independent experiments in triplicate is represented on the right panel. (B) Differential modulation of Gal-3-induced apoptosis by
CD6 isoforms. Same as in A, but using GST-Gal3 (100 lg/ml). (C) Absence of apoptotic effects by GST. Same as in A, but using GST (100 lg/ml). In all cases statistical
comparisons were made using an unpaired t-test. ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
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Fig. 5. Gal-1 and -3 bind to membrane-bound CD6. (A) Analysis of CD6 surface expression in parental and CD6-transfected 2G5 cells expressing WT (2G5-CD6.WT) or
cytoplasmic tail-truncated (2G5-CD6.V463stop) isoforms. Histograms show ﬂuorescence analysis of cells stained with FITC-labeled anti-CD6 mAb (aCD6) and IgG1 isotype
control (IC). (B) Binding of Gal-1 to CD6-transfectants. 2G5 cells (105) either parental or transfected with the CD6.V463stop variant (2G5-CD6+) were incubated with biotin-
labeled GST or GST-Gal1 (5 lg/ml) for 1 h, followed by staining with PE-streptavidin. Figure shows FACS histogram (left panel) for a representative experiment, and mean
ﬂuorescence intensity channel (MFI, right panel) averaged from duplicates of two independent experiments (C) Binding of Gal-3 to CD6-transfectants. Same as in B, but using
GST-Gal3 (5 lg/ml). Unpaired t-test was used for statistical comparisons. ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
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Fig. 7. Gal-1 and -3 interfere with allogeneic DC-mediated T cell proliferation.
Mature DC (2  103/well) were added to 96-well U-bottom plates and pre-
incubated for 30 min with SEB (1 lg/ml). Then, PBLs from unrelated donors (105
cells/well) previously stained with CFSE were added to the wells in the presence or
absence of increasing amounts (0.5, 5, and 50 lg/ml) of GST-Gal1, GST-Gal3, GST or
rshCD6. The proliferative response at day 5 was analyzed by FACS by quantifying
the percentage of CFSEhigh (resting) and CFSElow (proliferating) cells. Results are the
mean ± SD of n = 10 experiments performed and are expressed as percent (%) of
proliferation, considering 100% the percent of proliferating cells in the absence of
competitors (DC + SEB+PBLs). Statistical comparisons were made with the GST-
treated group and using an unpaired t-test. ⁄p < 0.002; ⁄⁄p < 0.001.
2812 C. Escoda-Ferran et al. / FEBS Letters 588 (2014) 2805–2813least the ALCAM-binding site of the SRCR3 domain of CD6, but not
the CD6-binding site located in the D1 domain of CD166/ALCAM.
The fact that Gal-1 and -3 paralleled the inhibitory effects of
soluble CD6 on the allogeneic APC-induced T-cell proliferative
response suggests that galectins could interfere with CD6-CD166/
ALCAM interaction, but this remains to be unequivocally proven.
The dissociation constant (Kd) of the interaction between CD6
and CD166/ALCAM is 0.4–1.0 lM [13], which is typical of immune
receptor-ligand interactions. A recent report states that the Kd of
the interaction of Gal-3 with DMBT1, a prototypical member of
the SRCR-SF, was 0.1–1.2 lM [35], which is in a similar range to
that of CD6-ALCAM. Although the Kd value for the galectin-CD6/
ALCAM interaction remains to be determined, galectins have low
afﬁnity for most ligands, as their interaction is bound to be
dynamic and reversible. This Kd is then expected to be in a similar
range to that of CD6-ALCAM, and thus this interaction could easily
be competed by galectins. Some results show that the interaction
of Gal-3 with CD6 has more pronounced effects than Gal-1. This
would be in agreement with the fact that, while Gal-1 can only
dimerize, Gal-3 can form larger oligomers (e.g. pentamers), thus
resulting in higher avidity interactions.
Literature shows that in the experimental conditions here used,
and although many interactions take place between different
receptors and co-receptors, cell proliferation can be signiﬁcantly
reduced by interfering only with the CD6-ALCAM interaction, for
example with soluble ALCAM or soluble CD6 [47,13,11]. This sug-
gests that although other interactions may be of importance, inhi-
bition of CD6-ALCAM is sufﬁcient to signiﬁcantly affect T-cell
proliferation induced by allogeneic DCs in the presence of superan-
tigen. Moreover, the magnitude of the observed effects for galec-
tins and soluble CD6 is comparable, suggesting that even though
galectins may bind to other receptors, their effect in this setting
is not stronger than that of soluble CD6 alone, and therefore might
be due to the sole inhibition of the CD6-ALCAM interaction.
Whatever the mechanism, the results open the possibility that
increased levels of Gal-1 and -3 may limit initiation and/or dura-
tion of T cell responses, thus reducing the damaging effects of
excessive and/or long-lasting immune reactions. This scenario
might be advantageous, and therefore operative, in certain tissues
continuously exposed to microbial aggressions such as the epithe-
lial barriers of the respiratory or the digestive tracts. In fact, avail-
able information indicates that both Gal-1 and -3 are known toskew the immune response towards the Th2 and/or Treg type
[46], which is the predominant response in the above mentioned
tissues under normal conditions.
The inhibitory effects of Gal-1 and -3 on T cell proliferation
assays are not due to decreased viability in these cells; this is also
true of experiments using rsCD6 and ALCAM-Fc, where inhibition
of cell proliferation is not accompanied by a decrease in cell viabil-
ity, as shown by previous reports [11,13,47]. Both Gal-1 and -3
have been reported however to induce apoptosis in T cells [36],
but the concentrations used in our proliferation assays are much
lower than those reported to induce apoptosis, suggesting that this
effect can be ruled out.
Moreover, our results also show that expression of CD6 protects
cells from apoptosis induced by exposure to high concentrations of
Gal-1 and -3. Interestingly, inhibition of galectin-induced apopto-
sis by CD6 expression requires integrity of its cytoplasmic tail,
since transfection of a cytoplasmic tail-truncated form not only
did not protect cells from apoptosis, but actually increased apopto-
tic cell levels. It is known that CD6 can contribute to leukemic B
cell (B-CLL) survival through the modulation of the Bcl-2/Bax ratio
[26]. In view of our results, this effect could also take place in T
cells, although further mechanistic studies are needed. The exis-
tence of naturally occurring truncated CD6 isoforms lacking certain
cytoplasmic signaling motifs has been reported in certain cell types
[7,6], and suggests that differential expression of these isoforms
could result in modulation of CD6-mediated phenomena.
In summary, a novel molecular interaction mediated by
galectins is reported, which adds another layer of complexity to
interactions between galectins and immune cell receptors. This
interaction may modulate cell adhesion, proliferation, differentia-
tion and other T cell-related events through competition of the
CD6-CD166/ALCAM interaction, likely resulting in changes in
ongoing immune responses.
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